Immutep (IMMP) Other Accumulated Expenses (2016 - 2025)
Immutep's (IMMP) quarterly Other Accumulated Expenses came in at $260764.9 in Q4 2025, down 46.39% YoY from $486442.3 in Q4 2024, and down 8.9% on a QoQ basis from $286241.0 in Q2 2025.
Immutep (IMMP) Other Accumulated Expenses (2016 - 2025) Analysis & Trends
Immutep (IMMP) has 3 years of Other Accumulated Expenses data on file, last reported at $260764.9 in Q4 2025.
- Quarterly Other Accumulated Expenses fell 46.39% year-over-year to $260764.9 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $260764.9 (down 46.39% YoY) and the FY2025 annual result came in at $286241.0, up 1.31% from the prior year.
- Other Accumulated Expenses eased to $260764.9 in Q4 2025, from $286241.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $486442.3 in Q4 2024 to a low of $260764.9 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 260,764.88 |
| Jun 30, 2025 | 286,240.98 |
| Dec 31, 2024 | 486,442.35 |
| Jun 30, 2024 | 282,529.07 |
| Mar 31, 2016 | -986,885.62 |